|
|
home > white papers > Protein Therapeutics - Reading Scientific Services Ltd (RSSL) |
 |
 |
WHITE PAPERS |
|
Reading Scientific Services Ltd (RSSL)
|
Protein Therapeutics
|
The use of protein-based biological materials to treat patients suffering from a wide range of diseases is one of the success stories of modern medicine. The diseases treated include diabetes (insulin), growth hormone deficiencies (recombinant human growth hormone), inborn errors of metabolism (glucosylceramidase, alpha-galactosidase), and red blood cell deficiency (erythropoietin). As the market develops, the number of biopharmaceutical products both being submitted for regulatory approval and reaching the end of their patent life is increasing.
|
|
|
|
|
 |
 |
News and Press Releases |
 |
Weiss Technik UK Ltd provides secure cold storage of Coronavirus vaccine
Loughborough, 23rd November 2020 - The UK
government has secured 40 million doses of the new Pfizer/BioNTECH
vaccine. Once available, the vaccine doses will have to be transported
and stored at -70 °C. This requires an uninterrupted cold chain. As a
long-standing partner of the pharmaceutical industry and specialist for
extreme temperatures, Weiss Technik UK Ltd offers suitable storage
solutions for this.
More info >> |
|
 |
White Papers |
 |
How To Increase Efficiency, Customer Satisfaction and Reduce Cost
AC Labels
A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
|